Skip to main content

Advertisement

Table 1 Clinically significant upper and lower GI events: primary analysis

From: GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial

   Celecoxib nsNSAID
   N Patients With Event n (%) N Patients With Event n (%)
All patients 4035 54 (1.3) 4032 98 (2.4)
H pylori status Positive 1401 25 (1.8) 1386 34 (2.5)
  Negative 2634 29 (1.1) 2646 64 (2.4)
OR (95% CI); P value 1.82 (1.31-2.55); p = 0.0003